Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bimekizumab in adults with palmoplantar pustulosis
2024-520337-80-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Palmoplantar Pustular Psoriasis (PPPP) comparing Bimekizumab with Placebo (2 arms). Primary endpoint: PPP-IGA 0/1 response at Week 16. Planned start Jan 2026; status: authorised.
02
Drugs
bimekizumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2024-520337-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520337-80-00.